Henlius Biotech

12:30 PM - 12:45 PM (EDT), Thursday, June 8, 2023 ・ Session Room 103
Henlius is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 1 has been approved for marketing in overseas markets (including EU), 18 indications are approved worldwide, and 3 marketing applications have been accepted under review in China, the U.S., and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialisation. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP.
Ticker:
2696.HK
Exchange:
HKEX
Company Type:
Not Provided
Company Website:
Company HQ State:
Shanghai
Company HQ Country:
China
Year Founded:
2010
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Serplulimab
Development Phase of Primary Product:
Multiple Products in Market
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
Chief Business Officer
Henlius Biotech